Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Strides Pharma Science Limited
WARNING LETTER
•Strides Pharma Science Limited•February 5, 2019

Strides Pharma Science Limited – FDA Warning Letter, Feb 5, 2019

Record Details

On July 1, 2019, the FDA issued a Warning Letter to Strides Pharma Science Limited following an inspection from January 28 to February 5, 2019, at their Puducherry, India facility. The inspection revealed significant violations of current good manufacturing practice (CGMP) regulations (21 CFR, parts 210 and 211), rendering their drug products adulterated under section 501(a)(2)(B) of the FD&C Act.

Key violations included: 1. **Inadequate Quality Control Unit (21 CFR 211.22(a)):** The Quality Unit (QU) lacked sufficient oversight. Investigators found discarded CGMP documents, including batch records for U.S. drug products, in a scrap yard, some dated just seven days before the inspection, without QU review. The firm's response was deemed inadequate for not assessing the full scope of discarded documents or the impact on distributed products. 2. **Failure to Thoroughly Investigate Discrepancies (21 CFR 211.192):** Out-of-specification (OOS) investigations were closed without adequate scientific justification. An example cited was an OOS for an API where an "old reagent" was identified as the root cause without reproducing the impurity or evaluating the original failing sample. The firm's response was inadequate, lacking supporting data for reserve

Company
Strides Pharma Science Limited
Inspection date
February 5, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Umesh Kale
View Company Profile

ID · 9094bd0f-e795-485b-8e95-4d89c54fc2a4

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.22(a)21 CFR 211.192FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Strides Pharma Science Limited
  • 483 - 2026-05-20May 20, 2026
  • 483 - 2022-12-05December 5, 2022
  • 483 - 2019-05-24May 24, 2019
  • 483 - 2017-05-26May 26, 2017
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Strides Pharma Science Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.